Profusa (NASDAQ:PFSA) Posts Quarterly Earnings Results

Profusa (NASDAQ:PFSA) posted its quarterly earnings results on Friday. The company reported ($2.05) earnings per share for the quarter, FiscalAI reports.

Profusa Stock Up 3.7%

Shares of PFSA stock traded up $0.02 on Friday, hitting $0.45. 132,518 shares of the stock were exchanged, compared to its average volume of 1,533,484. The company has a market capitalization of $1.96 million, a price-to-earnings ratio of 0.00 and a beta of 0.47. Profusa has a one year low of $0.40 and a one year high of $180.00. The firm has a 50 day moving average price of $0.70.

Analysts Set New Price Targets

Several research firms have recently weighed in on PFSA. Wall Street Zen upgraded Profusa from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 18th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Profusa in a research note on Friday, March 27th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

About Profusa

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.